The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia in chronic kidney disease.
Not Applicable
- Conditions
- Hyperuricemic patients with CKD
- Registration Number
- JPRN-UMIN000005573
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.The patients who are contraindicated to use febuxostat or allopurinol. 1)Patients who have liver injury(The ALT more than 200 IU/L) 2) Woman who is pregnat. 3) Patients who have allergy to febuxostat or allopurinol. 2. Patients who are judged as inadequate to participate the study by the their doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Serum Uric acid 2) Serum Cr, eGFR 3) Derum systatin C
- Secondary Outcome Measures
Name Time Method 1) Urinary protein/Cr ratio 2) Urinary tubular markers/Cr ratio 3) Urinary uric acid excretion ratio